Jazz Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem (sodium oxybate) oral solution titled “Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy.” The new patent, number 7,851,506, is also listed in the FDA's Approved Drug Products List.
In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product's formulation and Jazz Pharmaceuticals' distribution system. Six issued patents are now listed in the Orange Book. These patents expire from 2019 to 2024.
“Enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.